MedTrace Logo

Evaluating Dose Regimen of Intravenous Unfractionated Heparin and Low Molecular Weight Heparin in Critical Ill Patients Versus Critical Ill COVID-19 Patients Using Anti-Xa Levels.

NCT05224388 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 813

Last updated 2023-05-11

No results posted yet for this study

Summary

To see whether our increased dosing regimen of unfractionated heparin (UF) and low molecular weight heparin (LMWH) in COVID-19 patients was effective at preventing thrombo-embolic complications. We did regular anti-Xa tests to optimise the dose of our thromboprophylaxis. Furthermore, we want to examine the time it takes to reach adequate anti-Xa levels, to determine additional risk factors and do a subgroup analysis. Lastly, we will study if there are possible complications of our thromboprophylactic therapy.

Conditions

  • COVID-19
  • Deep Vein Thrombosis
  • Anticoagulants and Bleeding Disorders
  • Critical Illness

Interventions

DRUG

Enoxaparin

Use of enoxaparin in either prophylactic dose regimen or therapeutic dose regimen

DRUG

Heparin

Use of heparin in either prophylactic dose regimen or therapeutic dose regimen

Sponsors & Collaborators

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Harlinde Peperstraete, MD · University Hospital, Ghent

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2021-08-31
Completion
2022-09-15

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05224388 on ClinicalTrials.gov